http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 07:12:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24125+at+H.C.+Wainwright/26804451.html (Updated - July 23, 2026 7:12 AM EDT) <p>H.C. Wainwright analyst Andres Y. Maldonado raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $125.00 (from $105.00) while maintaining a Buy rating.</p><p>The analyst commented: 'Today, Monopar announced that it has initiated the rolling NDA submission for ALXN1840 in Wilson disease following FDA authorization to submit the application in completed sections. Importantly, this is not simply guidance that the submission process will begin shortly. Monopar has already submitted the first completed sections of the NDA, allowing FDA to begin reviewing those portions while the company finalizes the remainder of the application. ALXN1840 http://www.streetinsider.com/Analyst+PT+Change/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24125+at+H.C.+Wainwright/26804451.html Thu, 23 Jul 2026 07:12:48 -0400 MNPR http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24125+at+H.C.+Wainwright/26804451.html (Updated - July 23, 2026 7:12 AM EDT) <p>H.C. Wainwright analyst Andres Y. Maldonado raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $125.00 (from $105.00) while maintaining a Buy rating.</p><p>The analyst commented: 'Today, Monopar announced that it has initiated the rolling NDA submission for ALXN1840 in Wilson disease following FDA authorization to submit the application in completed sections. Importantly, this is not simply guidance that the submission process will begin shortly. Monopar has already submitted the first completed sections of the NDA, allowing FDA to begin reviewing those portions while the company finalizes the remainder of the application. ALXN1840 http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24125+at+H.C.+Wainwright/26804451.html Thu, 23 Jul 2026 07:12:48 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801927.html si-local-file:///var/storage/secattach/20260722/26801927.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801927.html Wed, 22 Jul 2026 16:17:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801927.html si-local-file:///var/storage/secattach/20260722/26801927.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801927.html Wed, 22 Jul 2026 16:17:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801933.html si-local-file:///var/storage/secattach/20260722/26801933.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801933.html Wed, 22 Jul 2026 16:17:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801933.html si-local-file:///var/storage/secattach/20260722/26801933.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801933.html Wed, 22 Jul 2026 16:17:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801913.html si-local-file:///var/storage/secattach/20260722/26801913.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801913.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801913.html si-local-file:///var/storage/secattach/20260722/26801913.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801913.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Monopar+Therapeutics+++++++++++++++++/26801917.html si-local-file:///var/storage/secattach/20260722/26801917.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Monopar+Therapeutics+++++++++++++++++/26801917.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Monopar+Therapeutics+++++++++++++++++/26801917.html si-local-file:///var/storage/secattach/20260722/26801917.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Monopar+Therapeutics+++++++++++++++++/26801917.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801922.html si-local-file:///var/storage/secattach/20260722/26801922.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801922.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801922.html si-local-file:///var/storage/secattach/20260722/26801922.html http://www.streetinsider.com/SEC+Filings/Form++S-8+POS++++Monopar+Therapeutics+++++++++++++++++/26801922.html Wed, 22 Jul 2026 16:16:00 -0400 MNPR O.46563693 http://www.streetinsider.com/Corporate+News/Monopar+begins+rolling+NDA+submission+for+Wilson+disease+drug/26798592.html <p>Monopar Therapeutics Inc. (Nasdaq: MNPR) has initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840 (tiomolibdate choline, TMC), a treatment for Wilson disease, the company said in a press release.</p><p>The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections to be reviewed while the company finalizes remaining sections. Monopar said it has already submitted the first completed sections.</p><p>ALXN1840 is described by the company as a first-in-class albumin tripartite complex (ATC) activator. If the NDA is accepted and approved, Monopar claims it would be the first http://www.streetinsider.com/Corporate+News/Monopar+begins+rolling+NDA+submission+for+Wilson+disease+drug/26798592.html Wed, 22 Jul 2026 08:02:10 -0400 MNPR http://www.streetinsider.com/FDA/Monopar+begins+rolling+NDA+submission+for+Wilson+disease+drug/26798592.html <p>Monopar Therapeutics Inc. (Nasdaq: MNPR) has initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840 (tiomolibdate choline, TMC), a treatment for Wilson disease, the company said in a press release.</p><p>The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections to be reviewed while the company finalizes remaining sections. Monopar said it has already submitted the first completed sections.</p><p>ALXN1840 is described by the company as a first-in-class albumin tripartite complex (ATC) activator. If the NDA is accepted and approved, Monopar claims it would be the first http://www.streetinsider.com/FDA/Monopar+begins+rolling+NDA+submission+for+Wilson+disease+drug/26798592.html Wed, 22 Jul 2026 08:02:10 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jul+22/26798514.html si-local-file:///var/storage/secattach/20260722/26798514.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jul+22/26798514.html Wed, 22 Jul 2026 08:00:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jul+22/26798514.html si-local-file:///var/storage/secattach/20260722/26798514.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jul+22/26798514.html Wed, 22 Jul 2026 08:00:00 -0400 MNPR O.46563693 http://www.streetinsider.com/Press+Releases/Monopar+Initiates+Rolling+NDA+Submission+for+ALXN1840+in+Wilson+Disease/26798425.html <p>WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company http://www.streetinsider.com/Press+Releases/Monopar+Initiates+Rolling+NDA+Submission+for+ALXN1840+in+Wilson+Disease/26798425.html Wed, 22 Jul 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Globe+Newswire/Monopar+Initiates+Rolling+NDA+Submission+for+ALXN1840+in+Wilson+Disease/26798425.html <p>WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company http://www.streetinsider.com/Globe+Newswire/Monopar+Initiates+Rolling+NDA+Submission+for+ALXN1840+in+Wilson+Disease/26798425.html Wed, 22 Jul 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Board+Changes/Monopar+adds+commercial+leaders+ahead+of+potential+ALXN1840+launch/26787247.html <p>Monopar Therapeutics (Nasdaq: MNPR) has added three commercial executives to its leadership ranks as the clinical-stage biopharmaceutical company prepares for a potential launch of its Wilson disease treatment, ALXN1840, pending FDA approval.</p> <p>Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to Monopar's Board of Directors at the company's Annual Meeting of Stockholders on June 22, 2026. The company also appointed Sharon Funk as Senior Vice President, Sales and Marketing, and Daniel Olmstead as Senior Vice President, Market Access, Distribution and Patient Services.</p> <p>Funk previously held a role in the commercialization of LUMRYZ at Avadel Pharmaceuticals, which was acquired by http://www.streetinsider.com/Board+Changes/Monopar+adds+commercial+leaders+ahead+of+potential+ALXN1840+launch/26787247.html Mon, 20 Jul 2026 08:00:12 -0400 MNPR http://www.streetinsider.com/Press+Releases/Monopar+Advances+Launch+Readiness+with+Addition+of+Veteran+Commercial+Executive+Nicole+Sweeny+to+Board+of+Directors+and+Expansion+of+Commercial+Leadership+Team%C2%A0/26787192.html <p>WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company’s Annual Meeting of Stockholders on June 22, 2026. In addition, Monopar has appointed Sharon Funk as Senior Vice President, Sales and http://www.streetinsider.com/Press+Releases/Monopar+Advances+Launch+Readiness+with+Addition+of+Veteran+Commercial+Executive+Nicole+Sweeny+to+Board+of+Directors+and+Expansion+of+Commercial+Leadership+Team%C2%A0/26787192.html Mon, 20 Jul 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Globe+Newswire/Monopar+Advances+Launch+Readiness+with+Addition+of+Veteran+Commercial+Executive+Nicole+Sweeny+to+Board+of+Directors+and+Expansion+of+Commercial+Leadership+Team%C2%A0/26787192.html <p>WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company’s Annual Meeting of Stockholders on June 22, 2026. In addition, Monopar has appointed Sharon Funk as Senior Vice President, Sales and http://www.streetinsider.com/Globe+Newswire/Monopar+Advances+Launch+Readiness+with+Addition+of+Veteran+Commercial+Executive+Nicole+Sweeny+to+Board+of+Directors+and+Expansion+of+Commercial+Leadership+Team%C2%A0/26787192.html Mon, 20 Jul 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770969.html <p>Cantor Fitzgerald analyst Kirsten Kluska reiterated an Overweight rating and $109.00 price target on Monopar Therapeutics (NASDAQ: MNPR)</p><p>The analyst commented, "Why meet? By the time of our conference, we believe MNPR will have submitted the NDA for ALXN1840 (tiomolybdate choline) in Wilson disease (genetic disorder of copper buildup). Thus, investors should get an update on the early stages of the review, but also be able to shift some of the discussion on how to properly frame the commercial opportunity, if approved. Where we'll differentiate: We still believe there is a lot of confusion amongst investors as to the specific analyses http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770969.html Wed, 15 Jul 2026 07:45:53 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html si-local-file:///var/storage/secattach/20260710/26758173.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html Fri, 10 Jul 2026 18:02:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html si-local-file:///var/storage/secattach/20260710/26758173.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html Fri, 10 Jul 2026 18:02:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html si-local-file:///var/storage/secattach/20260707/26741342.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html Tue, 07 Jul 2026 14:29:00 -0400 MNPR O.46563693